Overview of Dr. Samuel
Dr. Michael Samuel is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, and New York-Presbyterian Hospital. He received his medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 8 years. He is one of 378 doctors at New York-Presbyterian Hospital and one of 378 doctors at New York-Presbyterian Hospital who specialize in Oncology. He has more than 10 publications and over 500 citings.
Office
520 E 70th St
# Starr
New York, NY 10021Fax+1 646-962-0115
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2012 - 2015- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2009 - 2012
State University of New York Downstate Medical Center College of MedicineClass of 2009
Certifications & Licensure
NY State Medical License 2015 - 2026
Publications & Presentations
PubMed
- 59 citationsPrevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic TrioxideGail J. Roboz, Ellen K. Ritchie, Rebecca F. Carlin, Michael Samuel, Leanne Gale
Journal of Clinical Oncology. 2014-11-20 - 43 citationsArsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemiaGail J. Roboz, Ellen K. Ritchie, Tania J. Curcio, Juliette L. Provenzano, Rebecca F. Carlin
Cancer. 2008-11-01 - 66 citationsChanges in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaStefan K. Barta, Michael Samuel, Xiaonan Xue, Dan Wang, Jeannette Y. Lee
Annals of Oncology. 2015-05-01
Abstracts/Posters
- Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative NeoplasmsMichael B. Samuel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- CPX-351 As First Intensive Therapy for Elderly Patients with AMLMichael B. Samuel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Changes in Gut Microbial Diversity and Correlations with Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Receiving Intensive ChemotherapyMichael B. Samuel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
